Unsanctifying the sanctuary: challenges and opportunities with brain metastases

Shannon Puhalla, William Elmquist, David Freyer, Lawrence Kleinberg, Chris Adkins, Paul Lockman, John McGregor, Leslie Muldoon, Gary Nesbit, David Peereboom, Quentin Smith, Sara Walker, and Edward Neuwelt

Division of Hematology/Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania (S.P.); Department of Pharmaceutics, University of Minnesota, Minneapolis, Minnesota (W.E.); Department of Hematology/Oncology, Children's Hospital Los Angeles, Los Angeles, California (D.F.); Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland (L.K.); Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas (C.A.); Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University and the Mary Babb Randolph Cancer Center, Morgantown, West Virginia (P.L.); Department of Neurological Surgery, The Ohio State University Medical Center, Columbus, Ohio (J.M.); Blood Brain-Barrier Program, Oregon Health & Science University, Portland, Oregon (L.M., E.N.); Dotter Radiology/Neuroradiology, Oregon Health & Science University, Portland, Oregon (G.N.); Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Foundation, Cleveland, Ohio (D.P.); School of Pharmacy, Texas Tech University, Health Sciences Center, Amarillo, Texas (Q.S.); Department of Psychiatry, Oregon Health & Science University, Portland, Oregon (S.W.); Portland Veterans Affairs Medical Center, Portland, Oregon (E.N.)

Corresponding Author: Edward A. Neuwelt, MD, Blood-Brain Barrier Program, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, L603, Portland, OR 97239 (neuwelte@ohsu.edu).

While the use of targeted therapies, particularly radiosurgery, has broadened therapeutic options for CNS metastases, patients respond minimally and prognosis remains poor. The inability of many systemic chemotherapeutic agents to penetrate the blood-brain barrier (BBB) has limited their use and allowed brain metastases to become a burgeoning clinical challenge. Adequate pre-clinical models that appropriately mimic the metastatic process, the BBB, and blood-tumor barriers (BTB) are needed to better evaluate therapies that have the ability to enhance delivery through or penetrate into these barriers and to understand the mechanisms of resistance to therapy. The heterogeneity among and within different solid tumors and subtypes of solid tumors further adds to the difficulties in determining the most appropriate treatment approaches and methods of laboratory and clinical studies. This review article discusses therapies focused on prevention and treatment of CNS metastases, particularly regarding the BBB, and the challenges and opportunities these therapies present.

Keywords: brain metastases, CNS sanctuary, imaging, prevention, therapy.

Brain metastases are the most common intracranial tumor in adults and are 10 times more common than primary malignant CNS tumors, with at least 170,000 new cases reported in the United States each year.1 Up to 10% of all patients with advanced cancer (particularly lung and breast) will develop CNS involvement, with HER2-positive breast cancer patients having as high as a 30% incidence of brain metastases.2 Importantly, the incidence of CNS metastasis is increasing.3–6 While this is due in part to increased diagnoses from improved imaging techniques and the widespread availability of MRI, it also likely reflects improved overall survival (OS) in patients with better control of peripheral disease.1 Unfortunately, limited treatment strategies exist for management of sanctuary disease in the brain.2–5 Chemotherapy, radiation therapy, and surgery can result in small improvements in survival for a subset of patients, but many patients with CNS involvement die from neurological progression despite controlled systemic disease.6 The increased rate of diagnosis and lack of effective therapies are of significant concern.

The neurovascular unit (NVU), which consists of blood-brain barrier (BBB) endothelial cells and surrounding pericytes, astrocytes, and neurons as well as basement membrane and extracellular matrix, is heterogeneous in brain metastases. Tumor neovasculature has disorganized structure, basement membrane abnormalities, and dysfunctional tight junctions.7,8 Conversely, infiltrating metastatic cells can make use of the existing...
brain vasculature with a largely intact BBB. Inflammatory reactions to infiltrating tumor cells can also alter the permeability and function of the NVU. Heterogeneous NVU function and inflammation within the tumor mass at the proliferating edge of the tumor and peritumoral brain around tumor result in inconsistent delivery of imaging and therapeutic agents. This review discusses novel approaches for imaging, treatment, and prevention of CNS metastases.

Imaging of Brain Metastases

Magnetic Resonance Imaging

Contrast-enhanced MRI is the current gold standard for diagnosing CNS metastases (Fig. 1). However, 2 main challenges exist with regard to imaging CNS metastases. First is the differentiation between primary malignancies and solitary metastases. High-resolution gadolinium (Gd)-enhanced T1 and T2 fluid-attenuated inversion recovery imaging is highly sensitive, but only modestly specific, and is therefore not ideal for differentiation. The second challenge is determining tumor response to therapy and then differentiating response from recurrence or treatment-related changes. Radiological guidelines such as RECIST and Macdonald criteria for response assessment in solid tumors are inadequate for the CNS due to the unique anatomy of brain vasculature, including the BBB and the micro-environment of the NVU, as well as the inherent heterogeneity of brain metastases. Currently the updated Response Assessment in Neuro-Oncology (RANO) criteria are used for evaluation of brain metastases but remain controversial, particularly for assessing neuroinflammatory processes and the impact of vascular targeting agents. Various advanced MRI techniques have been tested to overcome these challenges. A case example describing these issues is shown in Fig. 1. This case is not atypical and illustrates a number of inherent challenges in the treatment of patients with brain metastases including drug delivery, effective imaging, and distinguishing response from progression or radiation-induced necrosis.

Neuroimaging techniques to assess peritumoral edema may be useful for differentiating metastases from gliomas and for assessing the impact of the infiltrative phenotype. While brain metastases show microscopic infiltration in the brain around tumor, the peritumoral areas comprise predominantly vasogenic edema. In contrast, gliomas show malignant cell infiltration throughout the peritumoral edematous region. This difference can be detected with proton magnetic resonance spectroscopy to assess tissue metabolites using single voxel or multivoxel chemical shift-imaging techniques. Minimal peritumoral edema in brain metastases may actually be associated with elevated levels of brain infiltration and decreased survival. Diffusion-weighted MRI to assess water molecule mobility can demonstrate changes in the apparent diffusion coefficient at the infiltrating edge of brain metastases and peritumoral brain that can provide a biomarker to assess response to radiation therapy and predict patient outcomes.

Dynamic susceptibility contrast-enhanced (DSC) perfusion-weighted imaging, when used to estimate relative cerebral blood volume (rCBV) in tumor and surrounding brain, has shown value for distinguishing primary from metastatic cerebral malignancies and assessing response to therapy. DSC adds little to no extra cost to a Gd-enhanced MRI scan while adding significant prognostic value. A number of studies have reported higher rCBV values in the enhancing component of high-grade gliomas than in metastasis, although there is high variability with some investigators showing no difference in rCBV in the tumor mass. In contrast, examination of the peritumoral edema region shows an even higher rCBV difference between gliomas and metastasis (1.31 vs 0.39, respectively [P = .001]) that may be diagnostic. These differences likely reflect the infiltrating angiogenic tumor cells in the peritumoral region of gliomas versus pure vasogenic edema in metastatic disease.

Relative cerebral blood volume analysis is also being used to differentiate progression from radiation injury or inflammatory responses to therapy (pseudoprogression). This is an important diagnostic dilemma that impacts prognosis and the decision to change therapies. Using a lesion rCBV threshold of 1.5–2.5 correlated with survival in the differentiation of tumor progression from chemoradiation injury. Further improvements in rCBV analysis may be obtained using preload or leakage correction algorithms with Gd-based contrast agents or ferumoxytol iron oxide nanoparticles that have no early leakage.

Varallyay et al recently described the use of ferumoxytol MRI to obtain a high-resolution, steady-state-CBVE image that differentiates regions of high vascularity and active tumor growth (Fig. 1B). Routine imaging following ferumoxytol administration can be limited by residual T1 and possibly T2 enhancement in the first week following administration and may persist for 4 weeks or longer in rare instances. The signal alterations are similar to common residual blood products in the subacute and chronic postsurgical patient. With pre-Gd T1 studies and foreknowledge of prior ferumoxytol administration, there is minimal issue with misdiagnosis in the follow-up imaging.

Positron Emission Tomography

Positron emission tomography (PET) to detect localized concentrations of tracers containing radionuclides such as 18F, 11C, or 13N can be used to diagnose and monitor CNS metastases. Standard PET imaging with the prototypical fluorodeoxyglucose (FDG) tracer is limited by high background glucose uptake in the brain, loss of PET avidity in previously irradiated areas in the brain over time, and high metabolic activity that is indistinguishable from active metastases in recently treated areas. A number of strategies are being investigated to overcome these limitations. The use of dual time point FDG-PET imaging is particularly useful for distinguishing malignancy from more benign causes of enhancement. Using dual-phase FDG-PET, the standardized uptake values of metastases, when compared with gray matter ratios as a function of time, was found to be >95% accurate for distinguishing between the lesion versus radiation necrosis (n = 25 patients). Integrated PET-MRI has been used in glioma but has not yet been reported in brain metastases.

Amino acid PET tracers may better differentiate normal brain from tumors because these regions show low and high amino acid uptake, respectively. Sensitivity and specificity upwards of 90% have been described with this method. PET may also be able to distinguish between treatment-related
changes and disease recurrence. Using O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) tumor-to-brain ratios, in combination with time uptake curves, correctly identified tumor versus necrosis (n = 21) versus metastatic tumor growth (n = 19) in 93% of cases. Similarly, 18-F-DOPA, with low physiological uptake but high tumor-to-normal-brain uptake, may have

---

**Fig. 1.** Relative cerebral blood volume (rCBV) to evaluate response in a brain metastasis. A 38-year-old woman with HER2-overexpressing, node-positive breast cancer was found to have an asymptomatic left frontal brain metastasis during screening MRI. The patient received multiple treatments including stereotactic radiosurgery, systemic therapy with lapatinib and docetaxel, whole brain radiation therapy, and i.v. trastuzumab and lapatinib, followed by recurrence each time. (A) Conventional T1-weighted MRI with gadolinium-based contrast (T1+Gd) showed a large mass. (B) Subsequent steady-state MRI with ferumoxytol showed increased rCBV along the superior and posterior margins of the thalamic lesion, indicative of active tumor (arrow). The patient was then started on trastuzumab-emtansine (T-DM1) an antibody drug conjugate. Three weeks later, there was a partial response with 50% decrease of the enhancing area on MRI and a marked decrease in CBV on steady-state MRI.
greater accuracy than 18F-FDG for identifying recurrence versus radiation necrosis. Specific PET tracers may be used to detect membrane changes consistent with apoptosis as an indication of therapeutic response. PET-radiolabeled pharmaceuticals may potentially be used for both imaging and treat brain metastases. For example, imaging (89Zr)-trastuzumab in the brain metastases of patients with HER2-positive breast cancers showed specific tumor localization. Uptake by brain metastases are 18-fold higher than in normal brain. There are many challenges inherent to imaging brain metastases, but there are also many opportunities for improvement as well. New techniques can be helpful for distinguishing the etiology of CNS lesions and assessing the response to therapy, but there have been difficulties implementing these techniques in national clinical trials. Collaboration between institutions involved in brain metastases imaging trials will be the key to moving these imaging strategies forward.

**Radiation Therapy for Brain Metastases**

Whole brain radiotherapy (WBRT) is a successful strategy for both primary prevention (eg, prophylactic cranial irradiation for small cell lung cancer [SCLC]) and secondary prevention (eg, after surgical resection or stereotactic radiosurgery [SRS] for limited metastases) of CNS metastases. Over the past decade, management of CNS metastases has shifted from universal use of WBRT to techniques that allow targeting individual lesions, such as MRI SRS techniques, which allow application of high doses of radiation with appropriate safety to surrounding brain. Use of SRS without WBRT was a controversial concept because it was believed that there would be multiple, diffuse areas of spread once tumor cells had breached the BBB, even if it had not been detected. Randomized trials have confirmed that survival is similar for patients with 1–4 lesions (treated with SRS with or without additional WBRT), and a recent meta-analysis has indicated that addition of WBRT is more effective for controlling metastatic recurrence than SRS alone (but there was no survival benefit). In contrast, patients receiving WBRT showed decreased quality of life and cognitive function.

SRS can provide significant tumor control, but patients can still progress despite this treatment. Laser interstitial thermal therapy (LITT), using image-guided, localized hyperthermia to kill tumor cells, may provide a novel treatment strategy for primary and metastatic CNS disease. There appear to be advantages for LITT over SRS in glioma patients, including potential for better treatment planning and efficacy. Pilot studies suggest the feasibility of LITT in the control of brain metastases.

Future research may be directed at utilizing the effects of a modest dose of radiation on the BBB to enhance the outcome of therapy by improving drug delivery and potentially improving an immune response in the CNS. This speculative use could be investigated with technologies such as a computed tomography-guided small animal irradiator, which can administer partial brain treatment such that drug penetration and other markers can be assessed in both the irradiated and non-irradiated areas of the same animal. Several preclinical and clinical studies suggest that the nature of the postradiation immune response may impact tumor control despite the immune-privileged properties of the brain. More information about the extent, dose-effect, and timing of BBB and immune effects is needed to inform the design of a clinical study that would test this approach.

**Novel Chemotherapy and Targeted Therapy Approaches for Brain Metastases**

There is a compelling rationale for studying systemic therapies that may sufficiently penetrate the BBB to elicit a clinical response in the CNS that matches the response elsewhere in the body. Although it is unlikely that current chemotherapeutic or targeted agents will replace radiotherapy and surgery as the primary means for obtaining durable control, use of such agents may allow delay of radiation or may improve lesion response magnitude or duration when used in conjunction with SRS or WBRT. More importantly, an agent capable of inducing response in gross lesions may have sufficient activity to sterilize micrometastatic disease in some patients, thereby reducing the incidence of brain metastasis when administered earlier in the disease course or of additional lesions in patients receiving SRS.

Advances in diagnosis, chemotherapy, radiation, and surgery have improved, and will continue to improve, the long-term survival for individuals with CNS metastases. Cognitive deficits are common among individuals with CNS cancers, and perceived cognitive dysfunction (“chemo brain”) can directly affect the quality of life for cancer survivors. In addition to the neuropathology itself, neurotoxicity can occur after WBRT. Whether used in treatment and/or prophylaxis for CNS metastases, the long-term cognitive and emotional consequences of radiotherapy have likely been underestimated. Cognitive decrements can also accompany some chemotherapeutic treatments, and both cognitive and affective side effects have been noted with adjuvant treatments (eg, steroids, antiepileptic drugs). These results underscore the necessity of evaluating, monitoring, and addressing cognitive impairment in this population.

**Lung Cancer Central Nervous System Metastases**

Lung cancer is the most common cancer to metastasize to the brain. Pemetrexed is a folate antimetabolite that is commonly used for the treatment of non–small cell lung cancer (NSCLC). Despite some reports showing low cerebrospinal fluid (CSF) concentration and limited efficacy, a number of studies have suggested benefit from pemetrexed in combination with other chemotherapies and radiation. In combination with WBRT, which could increase permeability of the BBB, intracranial response rates with pemetrexed and cisplatin combinations were nearly 70%, with extended progression free survival (PFS) and OS. Larger studies with pemetrexed, both in combination with radiation and as a single agent, are warranted to further explore this potential activity. Pemetrexed treatment is also associated with nearly 50% lower odds of subsequent brain metastases over non–pemetrexed-containing regimens in the first line setting of NSCLC.

There are promising data using tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), which is constitutively active in 10%–15% of lung cancers due to a mutation. Erlotinib and gefitinib cross the BBB with
sufficient CSF concentrations for potential efficacy.47 Retrospective studies in Asian nonsmokers, who have a higher incidence of EGFR mutations, have demonstrated intracranial response rates of 10%–70%.58 Patients with brain metastases from NSCLC demonstrated an overall response rate of 86% with erlotinib in combination with WBRT and a median survival of 11.8 months.69 Of interest, EGFR-mutations may be associated with a higher incidence of brain metastases.60 A retrospective analysis on the outcome of patients with known EGFR mutations and brain metastases reported a lower risk of CNS progression in patients who had received either gefitinib or erlotinib.51 In contrast, a phase 3 trial of unselected patients did not show any benefit from adding erlotinib to radiation, and there was a suggestion of a potential detriment on outcome.52

Melanoma Central Nervous System Metastases

Malignant melanoma will frequently metastasize to the brain, with overall incidence of 5%–8% and involvement in 40%–50% of patients with advanced disease.1 Historically, the treatment of melanoma brain metastases has been difficult because these tumors are less radiosensitive, and systemic therapy options for melanomas have been scarce until recently.53 Harnessing the patient’s own immune system to fight cancer is showing promise in the treatment of melanoma patients, including those with CNS involvement.54–56

Immune modulation approaches include monoclonal antibodies (mAbs) to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) (eg, ipilimumab) and the programmed death receptor (PD-1) (eg, nivolumab, pembrolizumab).57,58 These mAbs enhance the T cell immune response but have differing response rates and toxicity. In a phase 2 trial of ipilimumab in metastatic melanoma, the CNS disease control rate was 24% in neurologically asymptomatic patients with 7.0 month OS, similar to that seen in patients without brain metastases.59 In contrast, disease control was 5%, and OS was 3.7 months for patients whose CNS lesions induced neurological symptoms that required the use of steroids. Another phase 2 trial added fotemustine to ipilimumab for patients with melanoma brain metastases and showed a 50% intracranial control rate, a 40% objective CNS response rate, and an OS of 13.4 months.55 The results of these studies are promising, and further trials with additional combinations are anticipated.

Another recent breakthrough in the treatment of metastatic melanoma is the use of TKIs targeting the BRAF pathway. Approximately 50% of melanoma patients have activating mutations in either Val600Glu or Val600Lys of the BRAF oncogene that confer sensitivity to the BRAF inhibitors dabrafenib and vemurafenib.50,61 In a large study of 172 patients, the intracranial response rate was 39% in Val600Glu patients with no previous local treatment (OS > 8 months) and 31% in patients with progression after local treatment.60 In contrast, those patients with Val600Lys had much lower response rates (6.7% in previously untreated and 22% in progressive tumors [OS, 4 months]). Notably, 2 patients with a Val600Glu mutation achieved an intracranial complete response.60 BRAF inhibitors appear safe used in conjunction with radiotherapy in melanoma brain metastases.62

Breast Cancer Central Nervous System Metastases

There is disparity in outcome for CNS metastases depending on the subtype of primary breast cancer.63 As such, recent clinical trials researching breast cancer brain metastases have been subtype specific, with particular focus on HER2-positive disease. The TK1 lapatinib has undergone extensive clinical evaluation in breast cancer brain metastases. Typical phase 2 results are PFS of approximately 5 months and CNS objective responses ranging from 21%–31%.64 Lapatinib is often used in conjunction with capecitabine chemotherapy.65–68 Both agents penetrate the BBB, although delivery is variable, and response may be partially dose limited.67–69 In patients who had progressive brain metastases (despite prior radiation and trastuzumab-based therapies, n = 242), lapatinib alone resulted in 21% of patients having a CNS volumetric reduction response of ≥20%, while patients who received capecitabine plus lapatinib had a CNS volumetric response of ≥ 40%.70 In previously untreated HER2-positive brain metastases receiving combination capecitabine and lapatinib, 66% of patients achieved a CNS partial response defined as > 50% volumetric reduction.65 Newer brain-penetrating TKIs (eg, neratinib and afatinib) are currently being evaluated in HER2-positive brain metastases.70,71

The anti-HER2 mAb trastuzumab has not shown effectiveness against HER2-positive breast cancer brain metastases, but trastuzumab emtansine (T-DM1), an antibody drug conjugate of trastuzumab linked to a microtubule-disrupting agent, may be beneficial for a subset of patients. Case reports have shown responses to T-DM1 in radiation-naïve CNS lesions72 and in heavily pretreated patients (Fig. 1). In the recently reported TH3RESA trial, relative to physicians’ choice of chemotherapy, T-DM1 improved outcomes in patients with history of CNS metastases, (median PFS improved from 2.4 to 5.8 months).73 Similarly, subset analysis of the EMILIA trial that compared T-DM1 to the lapatinib/capecitabine combination (a typical standard for HER2+ CNS metastases) showed similar rates of CNS progression in both trial arms. In patients with history of treated and stable brain metastases at study entry, T-DM1 improved survival over lapatinib/capecitabine.74 Preclinical studies suggest that combination of HER2-targeted TKIs with mAbs or mAb conjugates may further improve efficacy in CNS disease.

Triple negative breast cancer (TNBC) also has a propensity for CNS metastasis. Unlike HER2-positive disease, there is no specific chemotherapy or biological target for TNBC, resulting in limited systemic regimens and few therapies targeting TNBC brain metastases. The combination of irinotecan topoisomerase inhibitor with iniparib (a putative PARP inhibitor that modulates reactive oxygen species metabolism) produced an intracranial response rate of 12% and an intracranial clinical benefit rate of 27% in a study of 34 TNBC patients with brain metastases.75 Iniparib has been discontinued, but the concept remains viable. Another potential approach is antiangiogenic therapy, such as bevacizumab anti-VEGF mAb, in combination with chemotherapy or radiotherapy.76 In a study of HER2-positive and TNBC brain metastases, bevacizumab plus carboplatin produced a CNS composite response rate of 63%. PFS remained short at 3.7 months; however, there was a subset of patients with prolonged clinical benefit who remained on therapy for up to 19 cycles.
Recommendations and Future Directions

Strategies to advance the study of chemotherapeutics in the treatment of brain metastases must include collaborative efforts to conduct trials. First, patients with brain metastases should be allowed to enroll in phase 1 trials, which have traditionally excluded patients with CNS disease. This inclusion does not lead to higher toxicities or premature closure of such trials but does provide a wider range of clinical research opportunities for evaluating the CNS activity of novel agents. Second, working groups are needed that focus on the management of brain metastases; an example of such a team is the US National Cancer Institute (NCI)-sponsored Brain Metastasis in Breast Cancer Working Group, which combines translational and clinical investigators from the NCI and academic institutions. Third, cooperative groups must form novel collaborations. The recent realignment of the NCI cooperative groups provides an opportunity for new collaborations, which may increase the number of studies of chemotherapy in brain metastases.

Preclinical Models of Brain Metastases

While the process of brain metastasis is poorly understood, we do know that it is an extremely selective, inefficient, multistep process that involves (i) breaking away of individual cells from the primary carcinoma, (ii) arrest or seeding of cells in the cerebrovasculature, (iii) extravasation of the cancer cell into the brain parenchyma, and (iv) colonization and growth in brain parenchyma. In vitro assays of migration or invasion fail to replicate the complexity of the NVU, hemodynamic variables, or the role of the immune system. In order to develop alternative therapies targeted to the different steps in brain metastasis, preclinical and translational research must develop more and better models.

The majority of brain metastasis studies are based upon direct intracerebral injection of tumor lines that were isolated and established years ago. Orthotopic models are useful for assessing therapies and vascular targeting in established metastases. Figure 2 shows a rat model of intracerebral SCLC xenograft used to assess the impact of bevacizumab on rCBV (as determined by DSC-MRI) and the cerebrovasculature (as determined by histology). However, xenograft models bear little relationship to natural in vivo processes involved in brain metastasis, and their predictive accuracy is open to question.

There are models of spontaneous and induced brain metastases in rodents for melanoma, lung cancer, and mammary cancers (Table 1). Spontaneous models, such as seeding from...
orthotopic or subcutaneous xenografts, can provide information about the process of intravasation and organotropism.82–85 The advantage of syngeneic models is that they allow for studying immune system interaction within the animal, as well as the role of the intact BBB and BTB; however, the applicability of these models for studying human disease is unclear. Model systems that utilize ectopic (bloodstream) injection of human cancer cells produce hematogenous brain metastases.7,10,86–90 Ectopic models have the advantage of allowing visualization of the fate of individual cancer cells as they bind to brain vasculature and infiltrate into brain parenchyma.7,91,92 A recent review describes new animal models to investigate mechanisms of brain metastasis.81

After intracardiac or intracarotid infusion, brain-seeking metastatic breast cancer sublines (MDA-MB231BR) circulate in the peripheral vasculature, arrest in brain capillaries, extravasate across the BBB, and develop multiple metastatic lesions predominantly in brain (Figs. 3 and 4).10,89 Pretreatment with cyclophosphamide to further decrease host immune response may enhance hematogenous brain metastasis formation in athymic rats.89,93 When MDA-MB231BR contrast-enhancing brain metastases in mice were compared with resected

Table 1. Selected brain metastasis preclinical models

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Origin</th>
<th>Route of Administration</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>A549</td>
<td>Human lung adenocarcinoma</td>
<td>Orthotopic lung xenograft, spontaneous brain metastases</td>
<td>84</td>
</tr>
<tr>
<td>A549</td>
<td>Human lung adenocarcinoma</td>
<td>i.v., tail vein</td>
<td>87</td>
</tr>
<tr>
<td>EBC-1</td>
<td>Human squamous cell NSCLC</td>
<td>i.v., tail vein</td>
<td>87</td>
</tr>
<tr>
<td>PC14-PE6</td>
<td>Human lung adenocarcinoma</td>
<td>Carotid artery</td>
<td>7</td>
</tr>
<tr>
<td>H460 (HTB177)</td>
<td>Human large cell NSCLC</td>
<td>Carotid artery</td>
<td>7</td>
</tr>
<tr>
<td>MCF-7 variants</td>
<td>Human breast cancer</td>
<td>Subcutaneous, spontaneous brain metastases</td>
<td>83</td>
</tr>
<tr>
<td>MCF-7</td>
<td>Human breast cancer</td>
<td>Intracardiac or carotid artery</td>
<td>86,90</td>
</tr>
<tr>
<td>4T1</td>
<td>Mouse breast carcinoma</td>
<td>Mammary fat pad, spontaneous brain metastases.</td>
<td>85</td>
</tr>
<tr>
<td>4T1 variants</td>
<td>Mouse breast carcinoma</td>
<td>Intracardiac or carotid artery</td>
<td>10,86</td>
</tr>
<tr>
<td>MDA-MB231 variants</td>
<td>Human breast cancer</td>
<td>Intracardiac or carotid artery</td>
<td>10,86,88–91</td>
</tr>
<tr>
<td>WM239A variants</td>
<td>Human melanoma</td>
<td>Orthotopic xenograft, spontaneous brain metastases</td>
<td>82</td>
</tr>
<tr>
<td>A2058</td>
<td>Human melanoma</td>
<td>Carotid artery</td>
<td>7</td>
</tr>
</tbody>
</table>

Abbreviation: NSCLC, non-small cell lung cancer
human brain metastases of breast cancer (n = 16 human cases), they were found to have nearly equal rates of apoptosis, cellular growth, and neuroinflammatory response.88

Model systems such as these94 may provide significant insight into potential targets for the prevention of brain metastases of breast cancer. The drawback of rodent models of human tumor metastasis is that immunodeficient rodents must be used. Therefore, the influence of the immune system, which is likely a major influence in human systems, is lost. Of interest, even though these cell lines reliably produce brain metastases in mice, only a small percentage of injected cells actually form measurable tumors. Most cells fail to bind to or transmigrate the cerebrovasculature or remain as dormant single cells once they enter the brain parenchyma, which suggests that the development of CNS metastasis is an inefficient process overall.91

Use of Preclinical Models in Drug Pharmacokinetics

Current drug development programs typically demonstrate proof of concept in vitro and then dose to the maximum level for drug efficacy studies in vivo, when such concentration can rarely be obtained in humans. Standard pharmacokinetic practices focus on the total drug level in plasma, with minimal assessment of distribution of the agent in brain metastases or whole brain (an agent is often said to either cross or not cross the BBB). Brain drug levels, when assessed, are rarely expressed in terms of free drug concentration or correlated in pharmacokinetic-pharmacodynamic (PK-PD) models to better predict drug efficacy. The majority of drug delivery and sensitivity studies have used intracerebrally implanted brain metastasis models that poorly replicate the variety of human brain metastases.

To improve predictive accuracy of chemotherapeutic drug assays and models, greater attention must be placed on the actual concentration of drug that reaches key sites within the tumor and the extent to which this concentration is effective. Surgical efforts to quantitate drug entry into metastases suffer from artefact introduced by the surgical disruption of the BBB and BTB.57 Thus, drug-delivery imaging methods are needed that will accurately report the extent of brain metastasis drug exposure (and not simply the shape of the tumor or the extent of its barrier integrity). Care must be taken to account for the heterogeneity of drug delivery within tumors due to BBB compromise. In hematogenous models of metastatic breast cancer, the dysfunctional BTB still limits drug delivery of taxanes, anthracyclines, and lapatinib to 2%–15% of that in systemic metastases.10,68 In only a small subset of brain metastases (<20%) did chemotherapeutic drug concentrations approach those of systemic tumors and show signs of drug-induced efficacy. A clinical study documented inconsistently cytotoxic concentrations of lapatinib and capecitabine in breast cancer brain metastases of women treated with those agents preoperatively.

It is important to consider interventions that raise the concentrations of drugs targeting brain metastases to an appreciable degree (ie, >10 fold).10,68 Close correlation of drug concentration with in vivo biomarkers of efficacy will permit development of rational PK-PD models that better demonstrate the limiting factors in drug efficacy and the extent to which limited drug delivery must be overcome. For many agents, the delivery deficit is not 2–3 fold, but rather 10–50 fold, under-scoring the need for better focus and creative thinking toward targeted, novel drug delivery solutions. Potential strategies include BBB disruption, inhibition, or modulation of active efflux transport and design of agents that are membrane permeable and not substrates to limiting efflux transporters.

Brain Metastases Prevention

Given the current failure rates of chemotherapy, surgery and radiation, the prevention of brain metastases (particularly in diseases such as HER2-positive breast cancer) is under active investigation. While the risk of brain metastases is only 5% for all women with a primary breast cancer, women who have stage IV HER2-positive or TNBC disease have a 20%–40% risk of developing brain metastases.95

An ideal prevention study would first need to randomize asymptomatic patients with high-risk disease (TNBC, HER2-positive breast cancer, high-grade melanoma, and lung cancer) to serial screening MRI (or other imaging) as compared with
those for whom CNS imaging was only done in the setting of neurological symptoms to confirm that early diagnosis (presumably of limited metastatic disease) would lead to improved outcomes. Once there was a historical control rate of development of metastatic breast cancer without known CNS involvement, who were screened every 3 months with MRI for the development of brain metastases. These patients were compared with a separate cohort who had received WBRT for symptomatic brain metastases. These patients were compared with a separate cohort who had received WBRT for symptomatic brain metastases. In this study, the OS of the 2 groups was similar (53 vs 51 months), but death from CNS involvement was significantly reduced (16% in the treated asymptomatic group vs 48% in the treated symptomatic group). None of the patients in this study received surgery or SRS, so the applicability of the findings to patients treated with those modalities is limited and does not reflect current US practice patterns. Larger studies and trials with a goal to intervene with novel systemic agents are needed. These trials require thoughtful design and multidisciplinary endorsement to avoid early closure due to poor accrual of these trials as noted in Table 2.

The CEREBEL trial highlights some of the important considerations with a CNS metastases prevention trial. This trial was designed with a primary endpoint of the CNS as a site of first relapse. The comparison was between a regimen with proven efficacy to cross the BBB (capecitabine/lapatinib) with a regimen that would not cross into the CNS (capecitabine/trastuzumab) but was otherwise a standard in HER2-positive systemic disease. Upfront screening for CNS involvement with a pre-enrollment MRI disqualified 20% of potential patients due to occult brain metastases. The incidence of developing HER2-positive CNS disease was low in both arms: 3% in the lapatinib/capecitabine arm and 5% in the trastuzumab/capecitabine arm. The low incidence, combined with better PFS in the trastuzumab-treated arm (HR, 1.30), prompted early termination of the study. The CEREBEL study demonstrated the need for relatively equal efficacy against systemic disease in the treatment arms. The combination of lapatinib with a taxane was inferior to trastuzumab and taxane in the EORTC 10054 study. Similarly, in the CEREBEL trial, the lapatinib-only arm was inferior from an overall efficacy standpoint, which likely limited the ability to show any improvement in the CNS endpoint. In the CEREBEL trial, 40% of patients had not received prior trastuzumab. Another potential consideration is that with a number of new, improved therapies, such as pertuzumab-anti-HER2 mAb, and T-DM1 mAb-drug conjugate controlling systemic disease longer in the metastatic setting, the best setting in which to study CNS metastases prevention may be later in the disease course. Perhaps initially studying CNS prevention, in the more advanced third line and beyond setting, would be more appropriate.

Alternative prevention strategies include blocking tumor cell adhesion to brain vasculature or infiltration across the BBB. Integrin cell adhesion dimers are basic components of cell cytoskeleton and signaling architecture and are essential for cell-cell and cell-ECM adhesion in the NVU. The αv integrins are associated with lung cancer brain metastasis and in the MDA-MB231BR hematogenous breast cancer brain metastasis model. Intetumumab, a monoclonal antibody targeting αv integrins, delayed the onset of breast cancer brain metastases in rats with the MDA-MB231BR hematogenous breast cancer brain metastasis model as determined by MRI (Fig. 4). Rats receiving intetumumab i.v. before or after cell infusion, or mixed with the cells prior to cell infusion (n = 24), developed significantly fewer metastases than untreated controls, with 7 rats (32%) showing no detectable brain tumors. The difference in brain metastasis incidence correlated with improved survival. These animal

### Table 2. Selected trials of chemoprevention for brain metastasis

<table>
<thead>
<tr>
<th>Title</th>
<th>Sponsor</th>
<th>ClinicalTrials.gov Identifier</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary prevention</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nab-paclitaxel and temozolomide plus oblimersen (melanoma)</td>
<td>Genta Incorporated</td>
<td>NCT00409383</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>Trastuzumab-radiotherapy</td>
<td>Centre Oscar Lambret</td>
<td>NCT01613482</td>
<td>Stopped due to poor accrual</td>
</tr>
<tr>
<td>Lapatinib/capecitabine vs trastuzumab/capecitabine (Her2+ breast)</td>
<td>GlaxoSmithKline</td>
<td>NCT00820222</td>
<td>Stopped early; very small number of events in both arms</td>
</tr>
<tr>
<td>Temozolomide (metastatic breast cancer)</td>
<td>Schering-Plough Italy</td>
<td>NCT00638963</td>
<td>Stopped due to poor accrual</td>
</tr>
<tr>
<td>Maintenance temozolomide vs observation (stage III/IV non-small cell lung cancer)</td>
<td>Schering-Plough Italy</td>
<td>NCT00632203</td>
<td>Completed</td>
</tr>
<tr>
<td>Stereotactic radiosurgery with sunitinib for brain metastases</td>
<td>University Health Network, Toronto</td>
<td>NCT00981890</td>
<td>Recruiting</td>
</tr>
<tr>
<td>Stereotactic radiosurgery → sunitinib (1-3 newly diagnosed brain metastases)</td>
<td>Cleveland Clinic</td>
<td>NCT00910039</td>
<td>Stopped due to poor accrual</td>
</tr>
<tr>
<td>Stereotactic radiosurgery → temozolomide (1–3 brain metastases)</td>
<td>University of Florida</td>
<td>NCT00717275</td>
<td>Stopped due to poor accrual</td>
</tr>
<tr>
<td><strong>Secondary prevention</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stereotactic radiosurgery with sunitinib for brain metastases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stereotactic radiosurgery → sunitinib (1-3 newly diagnosed brain metastases)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stereotactic radiosurgery → temozolomide (1–3 brain metastases)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maintenance temozolomide vs observation (stage III/IV non-small cell lung cancer)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Temozolomide (metastatic breast cancer)</td>
<td>Schering-Plough Italy</td>
<td>NCT00638963</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>Lapatinib/capecitabine vs trastuzumab/capecitabine (Her2+ breast)</td>
<td>GlaxoSmithKline</td>
<td>NCT00820222</td>
<td>Stopped early; very small number of events in both arms</td>
</tr>
<tr>
<td>Temozolomide (metastatic breast cancer)</td>
<td>Schering-Plough Italy</td>
<td>NCT00638963</td>
<td>Stopped due to poor accrual</td>
</tr>
<tr>
<td>Maintenance temozolomide vs observation (stage III/IV non-small cell lung cancer)</td>
<td>Schering-Plough Italy</td>
<td>NCT00632203</td>
<td>Completed</td>
</tr>
<tr>
<td>Stereotactic radiosurgery with sunitinib for brain metastases</td>
<td>University Health Network, Toronto</td>
<td>NCT00981890</td>
<td>Recruiting</td>
</tr>
<tr>
<td>Stereotactic radiosurgery → sunitinib (1-3 newly diagnosed brain metastases)</td>
<td>Cleveland Clinic</td>
<td>NCT00910039</td>
<td>Stopped due to poor accrual</td>
</tr>
<tr>
<td>Stereotactic radiosurgery → temozolomide (1–3 brain metastases)</td>
<td>University of Florida</td>
<td>NCT00717275</td>
<td>Stopped due to poor accrual</td>
</tr>
</tbody>
</table>
studies suggest that intetumumab can act directly on tumor cells and/or vasculature to prevent one or more of the steps in metastasis. Of note, there is not efficacy of this agent in terms of treatment of existing brain metastases. We feel that a clinical trial for the prevention of brain metastases with intetumumab should be considered.

Summary, Conclusions and Recommendations

As our understanding of cancer pathogenesis and treatment progresses, the need to understand the alterations and that confer a predisposition to CNS metastases becomes great. Evaluation of CNS metastases for metastatic homing signatures will allow researchers and clinicians to better understand the somatic mutations that may add in the pathogenesis or the predilection of CNS metastasis. Three important challenges currently need to be addressed. The first is the development of preclinical models that more accurately recapitulate CNS metastases for both biological and therapeutic studies. The second involves the sequencing of SRS and WBRT during radiotherapy and determining how local therapies can be delayed in order to allow assessment of new systemic treatments. Finally, the clinical trial challenges include image standardization to assess response, as well as inclusion of novel imaging paradigms. We wholeheartedly endorse the continued research evaluating systemic therapy options specifically for CNS metastases. We also strongly support the inclusion of patients with CNS metastases in clinical trials. We are optimistic that continued efforts toward understanding chemotherapeutic drug delivery, short- and long-term therapy toxicities, and the underlying biology of CNS metastasis will lead to new and improved therapeutic options for patients with CNS metastases.

Funding

Grants from the National Institutes of Health NIH/NIGMS U54GM104942, and R13 NS076353 (E.N.) and the Walter S. and Lucienne Driskill Foundation (E.N.). This report was based on presentations at the 19th Annual Meeting of the Blood-Brain Barrier Consortium (March 21–23, 2013, Stevenson, Washington), which was partially funded by the R13 grant.

Conflict of interest statement. The authors have no conflicts of interest to disclose.

References


71. Joensuu H, Ould-Kaci M, the TG. LUX-Breast 3: Randomized Phase II trial of afatinib (BIBW 2992) alone or with vinorelbine versus investigator’s choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases after trastuzumab and/or lapatinib-based therapy*. Cancer Res. 2012;72(24 Supplement):OT1–1–15.


